Evommune EVMN
NYSE EVMN
$5.18 -0.20 (-3.72%)
As of: Oct 21, 2026 · 3:59 PM EDT

Evommune (EVMN) Net Margin (2025)

Updated

Evommune's Net Margin was -529.77% in FY2025, up 424.63 percentage points from -954.40% in FY2024.

Analysis

Evommune (EVMN) Net Margin (2025) Analysis & Trends

  • Per Business Quant data, Net Margin in earlier years was -954.40% in FY2024.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 30.88%
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 21.86%
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 21.27%
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn -8.04%
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn 22.65%
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 16.30%
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 23.62%
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn -134.51%
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn -1.65%
10 Evommune 186.46 Mn -451.06 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 -124.75%
Mar 31, 2025 -485.23%
API Access

Evommune Net Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-margin&ticker=EVMN&period=max&api_key=YOUR_API_KEY